Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.biocon.com | |
Market Cap | 28,274.13 Cr. | |
Enterprise Value(EV) | 32,412.03 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 5.14 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 45.83 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 80.18 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.94 | Calculated using Price: 235.50 |
Dividend Yield | 0.21 | Period Ending 2022-03 |
No. of Shares Subscribed | 120.06 Cr. | 1,200,600,000 Shares |
FaceValue | 5 | |
Company Profile | ||
The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. |
1 Day |
|
+0.08% |
1 Week |
|
-3.88% |
1 Month |
|
-11.30% |
3 Month |
|
-14.72% |
6 Month |
|
-27.04% |
1 Year |
|
-34.56% |
2 Year |
|
-37.63% |
5 Year |
|
-22.44% |
10 Year |
|
+428.03% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.68 | 17.22 | 16.31 | 15.37 | 8.74 | 18.00 | 14.26 | 13.16 | 12.47 | |
Return on Capital Employed (%) | 15.75 | 15.30 | 13.93 | 12.59 | 8.92 | 16.11 | 14.35 | 11.30 | 9.93 | |
Return on Assets (%) | 8.47 | 8.72 | 7.96 | 7.64 | 4.55 | 9.25 | 6.94 | 5.73 | 5.11 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 3,027 | 3,271 | 4,034 | 4,838 | 5,181 | 6,098 | 6,706 | 7,627 | 8,433 | 9,628 | |
Non Curr. Liab. | 1,262 | 1,378 | 2,421 | 2,305 | 2,007 | 2,122 | 2,685 | 5,497 | 6,803 | 7,394 | |
Curr. Liab. | 1,380 | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,210 | 3,828 | 4,125 | |
Minority Int. | 82 | 172 | 266 | 376 | 468 | 609 | 677 | 881 | 1,038 | 1,212 | |
Equity & Liab. | 5,751 | 6,375 | 8,387 | 9,197 | 9,796 | 11,868 | 14,076 | 18,215 | 20,101 | 22,359 | |
Non Curr. Assets | 3,112 | 3,813 | 4,416 | 5,149 | 5,648 | 6,979 | 8,751 | 10,614 | 11,718 | 12,311 | |
Curr. Assets | 2,639 | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,600 | 8,382 | 10,048 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 5,751 | 6,375 | 8,387 | 9,197 | 9,796 | 11,868 | 14,076 | 18,215 | 20,101 | 22,359 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 2,877 | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,301 | 7,143 | 8,184 | 9,042 | |
Other Income | 56 | 53 | 84 | 157 | 206 | 414 | 508 | 605 | 689 | 258 | |
Total Income | 2,933 | 3,143 | 3,431 | 4,048 | 4,330 | 5,929 | 6,808 | 7,748 | 8,873 | 9,300 | |
Total Expenditure | -2,190 | -2,394 | -2,584 | -2,912 | -3,294 | -4,391 | -5,044 | -5,841 | -6,690 | -7,092 | |
PBIDT | 743 | 749 | 847 | 1,137 | 1,035 | 1,538 | 1,765 | 1,907 | 2,183 | 2,208 | |
Interest | -2 | -9 | -29 | -26 | -62 | -71 | -65 | -58 | -68 | -75 | |
Depreciation | -204 | -221 | -249 | -277 | -385 | -448 | -552 | -715 | -814 | -866 | |
Taxation | -107 | -96 | -142 | -162 | -157 | -212 | -315 | -222 | -212 | -285 | |
Exceptional Items | 105 | 161 | 195 | 68 | 13 | -111 | -58 | ||||
PAT | 431 | 528 | 587 | 672 | 432 | 1,002 | 900 | 926 | 979 | 924 | |
Minority Interest | -17 | -31 | -59 | -76 | -81 | -97 | -123 | -106 | -123 | -136 | |
Share Associate | 22 | 16 | 21 | 1 | -29 | -79 | -207 | -172 | |||
Other Related Items | |||||||||||
Consolidated Net Profit | 414 | 497 | 550 | 612 | 372 | 905 | 748 | 741 | 648 | 617 | |
Adjusted EPS | 3 | 4 | 5 | 5 | 3 | 8 | 6 | 6 | 5 | 5 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 471 | 561 | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | |
Cash Fr. Inv. | -376 | -938 | -509 | -1,142 | -499 | -684 | -714 | -1,559 | -3,625 | -1,699 | |
Cash Fr. Finan. | -9 | 426 | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | |
Net Change | 87 | 49 | -112 | 297 | -36 | -262 | 199 | 112 | 99 | -280 | |
Cash & Cash Eqvt | 474 | 557 | 463 | 758 | 710 | 449 | 659 | 825 | 897 | 654 |
Tue, 24 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find enclosed the press release titled Biocon Foundation Wins the Prestigious IHW Gold Award for Diseases Screening Initiative of the Year for 2022.The above information will also be available on the website of the Company at www.biocon.com. |
Mon, 23 Jan 2023
Voting Results And Scrutinizers Report On Postal Ballot In Continuation to our letter dated December 20 2022 seeking approval of the members by way of Postal Ballot through the remote e-voting process on the resolutions as set out in the Postal Ballot Notice dated December 19 2022 please find enclosed:1. Voting results pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulation) enclosed and marked as Annexure-1;2. Scrutinizers Report dated January 23 2023 pursuant to Section 110 of the Companies Act 2013 read with Rule 22 of the Companies (Management and Administration) Rules 2014 enclosed and marked as Annexure-2. |
Mon, 16 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 This is to certify that the details of securities dematerialized and rematerialized during the quarter ended December 31 2022 as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed.The certificate from our RTA i.e. M/s. KFin Technologies Limited (Formerly known as KFin Technologies Private Limited) dated January 4 2023 confirming the above is enclosed for your reference. |
Fri, 27 Jan 2023 |
|
|
|
|
|